Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Medical Specialties

Research outputs 2014 to 2021

Tumour biology

Publication Year

Articles 1 - 3 of 3

Full-Text Articles in Medicine and Health Sciences

Intense Exercise For Survival Among Men With Metastatic Castrate-Resistant Prostate Cancer (Interval-Gap4): A Multicentre, Randomised, Controlled Phase Iii Study Protocol, Robert Newton, Stacey A Kenfield, Nicolas H. Hart, June M Chan, Kerry S. Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A. Galvao, Charles J Ryan, Fred Saad May 2018

Intense Exercise For Survival Among Men With Metastatic Castrate-Resistant Prostate Cancer (Interval-Gap4): A Multicentre, Randomised, Controlled Phase Iii Study Protocol, Robert Newton, Stacey A Kenfield, Nicolas H. Hart, June M Chan, Kerry S. Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A. Galvao, Charles J Ryan, Fred Saad

Research outputs 2014 to 2021

INTRODUCTION: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC).

METHODS AND ANALYSIS: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatment-naïve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients …


Can Exercise Suppress Tumour Growth In Advanced Prostate Cancer Patients With Sclerotic Bone Metastases? A Randomised, Controlled Study Protocol Examining Feasibility, Safety And Efficacy, Nicolas H. Hart, Robert Newton, Nigel Spry, Dennis Taaffe, Suzanne K. Chambers, Kynan Feeney, David Joseph, Andrew D. Redfern, Tom Ferguson, Daniel A. Galvao May 2017

Can Exercise Suppress Tumour Growth In Advanced Prostate Cancer Patients With Sclerotic Bone Metastases? A Randomised, Controlled Study Protocol Examining Feasibility, Safety And Efficacy, Nicolas H. Hart, Robert Newton, Nigel Spry, Dennis Taaffe, Suzanne K. Chambers, Kynan Feeney, David Joseph, Andrew D. Redfern, Tom Ferguson, Daniel A. Galvao

Research outputs 2014 to 2021

Introduction

Exercise may positively alter tumour biology through numerous modulatory and regulatory mechanisms in response to a variety of modes and dosages, evidenced in preclinical models to date. Specifically, localised and systemic biochemical alterations produced during and following exercise may suppress tumour formation, growth and distribution by virtue of altered epigenetics and endocrine–paracrine activity. Given the impressive ability of targeted mechanical loading to interfere with metastasis-driven tumour formation in human osteolytic tumour cells, it is of equal interest to determine whether a similar effect is observed in sclerotic tumour cells. The study aims to (1) establish the feasibility and safety …


Exercise Medicine For Advanced Prostate Cancer, Nicolas H. Hart, Daniel A. Galvao, Robert Newton Jan 2017

Exercise Medicine For Advanced Prostate Cancer, Nicolas H. Hart, Daniel A. Galvao, Robert Newton

Research outputs 2014 to 2021

Purpose of review:

Exercise is a provocative medicine, known for its preventive, complimentary and rehabilitative role in the management of cancer. Impressively, exercise is also emerging as a synergistic and targeted medicine to enhance symptom control, modulate tumour biology and delay disease progression, with the potential to increase overall survival. Given the complex clinical presentation of advanced prostate cancer patients and their omnipresent comorbidities, this review describes the current and potential role of exercise medicine in advanced prostate cancer.

Recent findings:

Exercise has been shown to be safe, feasible and effective for advanced prostate cancer patients, inclusive of patients with …